Biotech China 2014

View Profile


Pre/Non Reviewed Papers, Proceedings

Year Title Authors
1. 2008 Evaluation of a deformable re-contouring method for adaptive therapy.
2. 2008 Molecular markers in head and neck cancer: p16 and vascular endothelial growth factor predict for improved outcomes following treatment.
3. 2008 Quantification of anatomic positional variation and movement over the course of external beam radiation.
4. 2008 Daily image guidance for intensity modulated radiation therapy (IMRT) for head and neck cancer.
5. 2008 Pilot study of carboplatin/radiotherapy plus 'dose-dense' pemetrexed for locally advanced non-small cell lung carcinoma (abstr. #7571).
6. 2008 Phase I trial of bortezomib (Velcade), cisplatin and radiotherapy for advanced head and neck cancer (abstr. #6028). Poster presentation and poster discussion abstract at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO), Chicago.
7. 2008 A phase I trial of the combination of the anti-angiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies (abstr. #2053).
8. 2008 Value of FDG-PET for detecting metastatic lesions in head and neck cancer (abstr. #6047). Poster presentation at the 2008 annual meeting of the American Society of Clinical Oncology (ASCO), Chicago.
9. 2008 A phase I study of gefitinib (Iressa) in combination with hypofractionated thoracic radiation therapy (HRT) with stereotactic body frame (SBF) immobilization in patients with advanced non-small cell lung cancer (NSCLC).
10. 2007 A phase I trial of patupilone (epothilone B) and concurrent radiotherapy for CNS malignancies. Poster presentation at the annual meeting of the American Society of Therapeutic Radiology and Oncology (ASTRO)
11. 2007 Phase II randomized trial of surgery followed by chemoradiation plus cetuximab for high risk squamous cell carcinoma of the head and neck (RTOG 0234).
12. 2007 Is intensity modulated radiation therapy superior to 3D conformal radiotherapy for locally advanced head and neck cancer treated with aggressive concurrent cisplatin/taxane chemotherapy?
13. 2007 Quality of Life (QOL) supercedes the classic predictors of survival in locally advanced non-small cell lung cancer (NSCLC)
14. 2007 Associations between radiation doses to pharyngeal regions and severe late toxicity in patients treated with concurrent chemoradiotherapy – an RTOG analysis
15. 2006 Risk of cardiac and pulmonary death after post-operative radiotherapy (PORT) for NSCLC: Analysis of the SEER program.
16. 2006 Randomized trial of amifostine in locally advanced NSCLC patients receiving chemotherapy and hyperfractionated radiation (HRT)
17. 2006 A phase I trial using the proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for high grade gliomas.
18. 2006 Phase I: Update of Weekly docetaxel, cisplatin, daily celecoxib, concurrent radiotherapy in advanced head and neck cancer (P015).
19. 2006 Improved hearing preservation with deescalated dose of fractionated stereotactic radiotherapy (SRT) in patients with acoustic schwannomas
20. 2006 Randomized trial of amifostine in locally advanced NSCLC patients receiving chemotherapy and hyperfractionated radiation
21. 2006 Utility of FDG-PET scans in staging and prediction of outcome in head and neck cancer.
22. 2006 Pre-treatment and treatment related risk factors for Severe Late Toxicity after Chemo-RT for Head and Neck Cancer
23. 2005 A Phase I study of Gefitinib (Iressa) in combination with hypofractionated thoracic radiation therapy (HRT) with stereotactic body fram (SBF) immobilization in patients with advanced NSCLC: Preliminary results on the first dose level.
24. 2005 Higher BED is associated with improved local-regional control and survival for NSCLC treated with chemoradiation:
25. 2005 What is the meaning of local control after chemoradiotherapy for locally advanced NSCLC?
26. 2005 Phase I study of weekly Docetaxel, cisplatin with daily celecoxib and concurrent radiotherapy for patients with locally advanced head and neck cancer.
27. 2005 . Impact of overall treatment time during concurrent chemoradiotherapy for locally advanced NSCLC
28. 2005 Neck dissection (without primary tumor resection) followed by concurrent chemoradiation for stage IV oropharynx carcinoma.
29. 2004 Unexpected excessive toxicity in a pilot study of accelerated conformal radiotherapy with concurrent chemotherapy for stage III NSCLC.
30. 2004 A randomized phase III trial to assess the effect of erythropoietin on local-regional control and survival in anemic head and neck cancer patients: Initial report of RTOG 99-03.
31. 2003 Amifostine as mucosal protectant in patients with locally advanced non-small cell lung cancer (NSCLC) receiving intensive chemotherapy and thoracic radiotherapy
32. 2003 Cisplatin dose delivery and survival in concurrent chemoradiation for stage III NSCLC: An RTOG secondary analysis.
33. 2003 Signaling pathways in NSCLC as a predictor of outcome and response to therapy.
34. 2003 Amelioration of radiation pulmonary fibrosis in a C57Bl murine model using antioxidant enzymes.
35. 2003 Phase III study of amifostine in patients with locally advanced non-small cell lung cancer (NSCLC) receiving chemotherapy and hyperfractionated radiation
36. 2003 PEG-Catalase/PEG-SOD Mixture attenuates radiation-induced mouse lung fibrosis but not pneumonitis.
37. 2003 The survival of patients treated for stage III non-small cell lung cancer in North America has increased during the past 25 years (abstr. #2557).
38. 2003 RTOG 9705, a phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIA non-small cell lung cancer (NSCLC) patients - promising long term survival results.
39. 2002 Initial non-surgical treatment for T3/T4 head and neck squamous cell carcinoma (HNSCC) does not compromise ultimate local control: the role of planned pathologic restaging and early surgical salvage.
40. 2002 Patterns of failure for resected advanced head & neck cancer treated by concurrent chemotherapy and radiation therapy
41. 2002 Self-reported symptom distress during treatment for head and neck squamous cell carcinoma (HNSCC)
42. 2002 Association between pathologic response to neoadjuvant chemoradiotherapy and long-term survival for stage III non-small cell lung carcinoma (NSCLC)
43. 2002 Weekly carboplatin and paclitaxel concurrent with radiation therapy (RT) for locally advanced head and neck squamous cell carcinoma (HNSCC)
44. 2002 Relative risk of stroke in head and neck carcinoma patients treated with external cervical irradiation (abstr. #950).
45. 2002 Tumor Characteristics Obtained using FDG-PET Imaging in Lung Cancer for 3D Radiotherapy.
46. 2002 Phase I/II trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancer
47. 2002 Combined Modality Therapy for Locally Advanced Oropharyngeal Carcinoma
48. 2002 Postoperative concurrent radiochemotherapy in high-risk SCCA of the head and neck
49. 2001 Concurrent Chemoradiation for Locally Advanced NSCLC in the RTOG Experience: Effect of Overall Treatment Time.
50. 2001 RTOG 9610: Phase II study of reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck
51. 2001 A secondary analysis of RTOG 86-10: does the extent of progression at the time of initiating salvage hormone therapy influence survival in patients with prostate cancer who failed initial treatment with irradiation?
52. 2001 A Phase I study of SPI-77 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer.
53. 2001 Tumor characteristics obtained using FDG-PET imaging in lung cancer and new strategies for 3D radiotherapy.
54. 2001 Immunoconjugates of Catalase Attenuate Radiation-Induced Pulmonary Fibrosis in C57Bl Mice.
55. 2001 Comparison of anatomic and metabolic tumor imaging in head and neck squamous cell cancer (HNSCC).
56. 2001 A phase III trial comparing whole-pelvic versus prostate only radiotherapy and neoadjuvant versus adjuvant total androgen suppression
57. 2001 Phase II Study of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II and IIIA Non-Small Cell Lung Cancer (RTOG 97-05).
58. 2001 A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.
59. 2000 The risk of brain metastases after definitive chemoradiation for locally advanced non-small cell lung carcinoma.
60. 2000 Pathologic response to preoperative chemoradiation worsens with anemia in non-small cell lung cancer (NSCLC) patients.
61. 2000 Does clinical and/or imaging response to induction chemotherapy predict ultimate outcome in locally advanced oropharynx carcinoma?
62. 2000 The utility of positron emission tomography (PET) scanning in the workup of head and neck cancer.
63. 2000 Optimizing supraclavicular coverage and lung sparing in the low anterior neck field. Proc.
64. 2000 Neoadjuvant hormone treatment does not compromise the benefits of subsequent androgen suppression with patients in prostate cancer who fail initial radiation therapy
65. 2000 Androgen ablation adjuvant to definitive radiotherapy in carcinoma of the prostate. Year 2000 update of RTOG phase III studies 86-10 and 85-31.
66. 2000 RTOG protocol 92-02: A phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate.
67. 2000 RTOG 9610: Phase I study of reirradiation (RRT) with concurrent hydroxyurea (HU) and 5-fluorouracil (FU) in patients with squamous cell cancer of the head and neck.
68. 2000 Preliminary results of a Radiation Therapy Oncology Group trial (RTOG) 9705, a phase II study of postoperative adjuvant therapy in patients with completely reseted stage II and stage IIIA non-small cell lung cancer
69. 2000 The utility of positron emission tomography (PET) scanning in the workup of head and neck cancer. Proc 5th Int Conf on Head and Neck Cancer
70. 2000 Neck management in an organ preservation trial for locally advanced oropharynx carcinoma. Proc 5th Int Conf on Head and Neck Cancer
71. 2000 Early results of a phase II trial of chemoradiotherapy for lcoally advanced oropharynx carcinoma: important prognostic value of T-stage.
72. 2000 Nasopharyngeal carcinoma treated with external radiotherapy (XRT), brachytherapy, and concurrent and adjuvant chemotherapy.
73. 2000 Treatment of advanced squamous cell carcinoma of the head and neck (SCCHN) with altered fractionation radiation therapy (AFRT) versus chemoradiation (CRT). Proc 5th Int Conf on Head and Neck Cancer
74. 2000 Aggressive cutaneous malignancies: implications for management of the fgacial nerve. Proc 5th Int Conf on Head and Neck Cancer
75. 2000 Cisplatin (P), etoposide (E), paclitaxel (T) and concurrent hyperfractionated thoracic radiotherapy (TRT) for patients (pts) with limited disease (LD) small cell lung cancer (SCLC):
76. 2000 A Phase I/II trial of accelerated radiation therapy and concurrent 96-hour infusional paclitaxel for unresectable squamous cell carcinoma of the head and neck (abstr #1676).
77. 2000 Induction chemotherapy for T4 oropharynx carcinoma in a prospective multimodality phase II trial:
78. 2000 Risk of brain metastases is higher with delayed thoracic irradiation for locally advanced non-small cell lung carcinoma (NSCLC)
79. 2000 Neoadjuvant paclitaxel-carboplatin plus irradiation (XRT) improves resectability and local-regional control over neoadjuvant paclitaxel alone for stage IIIA non-small cell lung carcinoma (NSCLC)
80. 2000 RTOG protocol 92-02: a phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate (abstr #1284).
81. 1999 Organ preservation for locally advanced oropharyngeal carcinoma: interim analysis of a University of Pennsylvania multimodality phase II trial.
82. 1999 A phase III study evaluating the efficacy of conventional radiation therapy with or without recombinant B-interferon for patients with locally advanced non-small cell lung cancer and poor prognostic characteristics
83. 1999 Long-term outcome for patients with locally advanced non-metastatic prostate cancer treated with adjuvant hormones and radiation therapy versus radiation therapy alone:
84. 1999 Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer
85. 1999 Chemoradiation with or without surgery for stage IIIA non-small cell lung carcinoma (NSCLC): a comparison of survival and patterns of failure.
86. 1999 Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen deprivation following standard radiation therapy for unfavorable prognosis carcinoma of the prostate.
87. 1999 Postoperative radiotherapy for non-small cell lung carcinoma does not lead to an excess rate of intercurrent death
88. 1999 Preliminary toxicity report of a Phase II trial of organ preservation multimodality therapy for locally advanced oropharyngeal carcinoma.
89. 1999 Dose escalating 7-week continuous infusion paclitaxel with concurrent once-daily radiation therapy for locally advanced squamous carcinoma of the head and neck.
90. 1999 Neoadjuvant chemoradiotherapy with carboplatin/paclitaxel prior to surgery for IIIA non-small cell lung carcinoma (NSCLC)
91. 1999 The importance of the “treatment package” time in surgery and postoperative radiotherapy for squamous cell carcinoma of the head and neck
92. 1998 The Efficacy of Postoperative Radiotherapy for Non-small Cell Lung Carcinoma (NSCLC) Resected with Positive Margins.
93. 1998 Risk factors for relapse and poor survival following postoperative radiation therapy for non-small cell lung cancer.
94. 1998 Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of Androgen Deprivation before and during Radiotherapy in Locally Advanced Carcinoma of the Prostate.
95. 1998 Are patients with supraclavicular node metastases in non-small cell lung cancer curable? -- an analysis of the Radiation Therapy Oncology Group (RTOG) experience.
96. 1998 A Comparison of Altered Fractionation Radiation Therapy vs. Chemoradiation for Unresectable Squamous Cell Carcinoma of the Head and Neck
97. 1998 A Phase I Trial of 96-hour Taxol Infusion plus Accelerated Radiotherapy for Unresectable Head and Neck Cancer.
98. 1998 Phase III Radiation Therapy Oncology Group (RTOG) Trial of Androgen Depravation before and during Radiotherapy in Locally Advanced Carcinoma of the Prostate.
99. 1997 Distinguishing Local Tumor Recurrence from Post-radiation Effects in Head and Neck Cancer using PET-FDG Imaging.
100. 1997 The Use of Positron Emission Tomography Imaging with 2-18F-fluoro-2-deoxy-D-glucose to Distinguish Post-Radiation Effects from Local Recurrence in Head and Neck Cancer.
101. 1997 Does Pretreatment Hemoglobin Level Affect Outcome in Patients with T1 Glottic Cancer?
102. 1997 Postoperative Radiotherapy after Wedge Resection of Non-small Cell Lung Carcinoma.
103. 1997 Utility of Gastrostomy Tubes for Patients Receiving Intensive Irradiation to the Head and Neck.
104. 1997 Does Pretreatment Hemoglobin Level Affect Outcome in Patients with T1 Glottic Cancer?
105. 1996 Combined Surgery and Postoperative Radiotherapy for Carcinoma of the Base of Tongue.
106. 1995 Radiotherapy with 6MV Photons for Early Glottic Carcinoma: Extension to Posterior One Third of the Vocal Cord Impacts Negatively on Local Control
107. 1994 Decreased Acute Toxicity by Midline Mucosa-sparing Blocks during Radiotherapy for Carcinoma of the Oropharynx, Oral Cavity and Nasopharynx
108. 1993 Inaccuracies in Using the Lumpectomy Scar for Planning Electron Boosts in Primary Breast Carcinoma


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.